EGFR mutation incidence in non-Small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII)

American Journal of Cancer Research

Volumn 5, Issue 9, 2015, Pages 2892-2911

  Midha, Anita ^a   Dearden, Simon ^a   McCormack, Rose ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Adenocarcinoma; EGFR mutation frequency; non small cell lung cancer

Indexed keywords

AFRICA; ARTICLE; ASIA; EGFR GENE; ETHNIC DIFFERENCE; EUROPE; FEMALE; GENE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NORTH AMERICA; PACIFIC ISLANDS; SEX DIFFERENCE; SMOKING; SOUTH AMERICA; SYSTEMATIC REVIEW;

EID: 84958643727     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (181)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014; 136: E359-E386.
2. Crin� L, Weder W, van Meerbeeck J and Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5: v103-v115.
3. Youlden DR, Cramb SM and Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3: 819-831.
4. Couraud S, Zalcman G, Milleron B, Morin F and Souquet PJ. Lung cancer in never smokers--a review. Eur J Cancer 2012; 48: 1299-1311.
5. Dearden S, Stevens J, Wu YL and Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371-2376.
6. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselaga J, Ochs JS and Haber DA. Epidermal growth factor receptor mutations and gene amplification in nonsmall- cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-8092.
7. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M and Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
8. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA and Kim ES. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28: 744-752.
9. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA and Bunn Jr PA. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007; 18: 752-760.
10. Hirsch FR and Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009; 10: 432-433.
11. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513- 2520.
12. Riely GJ, Politi KA, Miller VA and Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12: 7232-7241.
13. Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT, Looijen-Salamon MG, Ligtenberg MJ, Thunnissen FB, Heideman DA, de Weger RA and Vink A. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol (Dordr) 2012; 35: 189-196.
14. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M and Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496-1504.
15. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA and Dias- Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22: 2616-2624.
16. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia- Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M and Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
17. Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R and Mok TS. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer 2014; 83: 174-181.
18. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T and McCormack R. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014; 9: 1345-1353.
19. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L and You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
20. National Comprehensive Cancer Network. Practice guidelines in oncology-version V.3.2012 (non-small-cell lung cancer). Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Last updated 2012. Accessed 19 May 2015.
21. NICE. EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. Available at: http://www.nice.org.uk/guidance/dg9. Last updated 2013. Accessed 8 July 2015.
22. Marchetti A and Normanno N. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 2010; 102: 119-126.
23. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F and Stahel R. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010; 5: 1706-1713.
24. Eberhard DA, Giaccone G and Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 983-994.
25. Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, Guallar E, Lee G, Lee J and Shim YM. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One 2013; 8: e56011.
26. Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH and Heo DS. How molecular understanding affects to prescribing patterns and clinical outcome of gefitinib in non-small cell lung cancer? 10 year experience of single institution. Cancer Res Treat 2013; 45: 178- 185.
27. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9: 154-162.
28. Lam WK, White NW and Chan-Yeung MM. Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis 2004; 8: 1045-1057.
29. Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD and Gazdar AF. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 2007; 4: e125.
30. Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, Castro M, Avil�s A, Amorin E, Kirchuk R, Cuello M, Borbolla J, Riemersma O, Becerra H and Rosell R. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol 2011; 6: 1955-1959.
31. Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C and Wistuba II. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila) 2008; 1: 192-200.
32. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr and Ratain MJ. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65: 46-53.
33. Gebhardt F, Zanker KS and Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274: 13176-13180.
34. Qin BM, Chen X, Zhu JD and Pei DQ. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res 2005; 15: 212-217.
35. Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS and Guo BQ. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 4289-4294.
36. Wang Z, Wu YL, Zhang GC, Zhou Q, Xu CR and Guo AL. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients. Onkologie 2008; 31: 174-178.
37. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY and Wang J. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 2653-2659.
38. He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N and Xu J. Detection of epidermal growth factor receptor mutations in plasma by mutantenriched PCR assay for prediction of the response to gefitinib in patients with non-smallcell lung cancer. Int J Cancer 2009; 125: 2393-2399.
39. An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS and Wu YL. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012; 7: e40109.
40. Han CB, Ma JT, Li F, Zhao JZ, Jing W, Zhou Y and Zou HW. EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. Cancer Lett 2012; 314: 63-72.
41. Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang T, Han Y, Huang L, Zhu Y, Li X and Yan X. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int J Mol Sci 2013; 14: 24549-24559.
42. Liu Y, Wu BQ, Zhong HH, Hui P and Fang WG. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. Int J Clin Exp Pathol 2013; 6: 1880-1889.
43. Zhang H, Liu D, Li S, Zheng Y, Yang X, Li X, Zhang Q, Qin N, Lu J, Ren-Heidenreich L, Yang H, Wu Y, Zhang X, Nong J, Sun Y and Zhang S. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. J Mol Diagn 2013; 15: 819-826.
44. He Y, Li S, Ren S, Cai W, Li X, Zhao C, Li J, Chen X, Gao G, Li W, Zhou F and Zhou C. Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients. Lung Cancer 2013; 81: 162-166.
45. Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H and Chen J. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One 2013; 8: e52093.
46. Han B, Zhou X, Zhang RX, Zang WF, Chen ZY, Song HD, Wan HY and Zheng CX. Mutations of the epidermal growth factor receptor gene in NSCLC patients. Oncol Lett 2011; 2: 1233- 1237.
47. Cai YR, Zhang HQ, Qu Y, Mu J, Zhao D, Zhou LJ, Yan H, Ye JW and Liu Y. Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncol Rep 2011; 26: 877- 885.
48. McMillen E, Ye F, Li G, Wu Y, Yin G and Liu W. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected nonsmall cell lung cancer. Exp Lung Res 2010; 36: 531-537.
49. Li C, Sun Y, Fang Z, Han X, Fang R, Zhang Y, Pan Y, Zhang W, Ren Y, Ji H and Chen H. Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma. J Thorac Oncol 2011; 6: 1016-1021.
50. Xu JM, Han Y, Duan HQ, Gao EM, Zhang Y, Liu XQ, Zhang JS, Toschi L, Galetta D, Azzariti A and Paradiso A. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol 2009; 135: 771-782.
51. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, Lam WK, Chiu SW, Girard L, Minna JD, Gazdar AF and Wong MP. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006; 12: 1647-1653.
52. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP and Pik Wong M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115: 1723-1733.
53. Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T and Nishio M. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007; 131: 1628-1634.
54. Hosokawa S, Toyooka S, Fujiwara Y, Tokumo M, Soh J, Takigawa N, Hotta K, Yoshino T, Date H, Tanimoto M and Kiura K. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer 2009; 66: 107-113.
55. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H and Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3: 13-17.
56. Iwakiri S, Mino N, Takahashi T, Sonobe M, Nagai S, Okubo K, Wada H, Date H and Miyahara R. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 2009; 115: 2580-2593.
57. Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang CL and Date H. Clinical significance of BRAF gene mutations in patients with nonsmall cell lung cancer. Anticancer Res 2011; 31: 4619-4623.
58. Koga T, Takeshita M, Yano T, Maehara Y and Sueishi K. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. Int J Cancer 2011; 128: 1009-1017.
59. Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K and Sekido Y. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 2005; 50: 385-391.
60. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-8923.
61. Kosaka T, Yatabe Y, Onozato R, Kuwano H and Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009; 4: 22-29.
62. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, Suzuki K, Nakamoto M, Shimizu E, Minna JD and Yokota J. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007; 26: 5911-5918.
63. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513- 2520.
64. Mochinaga K, Tsuchiya T, Nagasaki T, Arai J, Tominaga T, Yamasaki N, Matsumoto K, Miyazaki T, Nanashima A, Hayashi T, Tsukamoto K and Nagayasu T. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil. Clin Lung Cancer 2014; 15: 136-144.
65. Nagashima O, Ohashi R, Yoshioka Y, Inagaki A, Tajima M, Koinuma Y, Iwakami S, Iwase A, Sasaki S, Tominaga S and Takahashi K. High prevalence of gene abnormalities in young patients with lung cancer. J Thorac Dis 2013; 5: 27-30.
66. Nakajima T, Yasufuku K, Nakagawara A, Kimura H and Yoshino I. Multigene mutation analysis of metastatic lymph nodes in nonsmall cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2011; 140: 1319-1324.
67. Nakamura R, Inage Y, Tobita R, Mori K, Numata T, Yanai H, Endo T, Ohtani H, Satoh H, Yuzawa K, Koizumi M and Ueki H. Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients. J Thorac Oncol 2014; 9: 1340-1344.
68. Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, Miyoshi T, Okumura S, Satoh Y, Nakagawa K, Nishio M, Horai T, Miyata S, Tsuchiya E, Fukayama M and Ishikawa Y. Correlation between morphology and EGFR mutations in lung adenocarcinomas. Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009; 63: 235- 240.
69. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, Watanabe S, Sakamoto H, Kumamoto K, Takenoshita S, Gotoh N, Mizuno H, Sarai A, Kawano S, Yamaguchi R, Miyano S and Yokota J. Identification of genes upregulated in ALKpositive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72: 100- 111.
70. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y and Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009; 4: 5-11.
71. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E and Miyagi Y. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007; 128: 100- 108.
72. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Yukiue H, Kobayashi Y, Yano M and Fujii Y. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer 2006; 54: 103-108.
73. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Kawano O, Yukiue H, Yokoyama T, Yano M and Fujii Y. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007; 58: 324-328.
74. Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, Matsumura A, Iuchi K, Takada M, Kawahara M, Kawaguchi T, Yukiue H, Yokoyama T, Yano M and Fujii Y. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol 2008; 134: 569-577.
75. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD and Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339- 346.
76. Sonobe M, Manabe T, Wada H and Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005; 93: 355-363.
77. Sugio K, Uramoto H, Onitsuka T, Mizukami M, Ichiki Y, Sugaya M, Yasuda M, Takenoyama M, Oyama T, Hanagiri T and Yasumoto K. Prospective phase II study of gefitinib in nonsmall cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 2009; 64: 314-318.
78. Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, Minna JD, Gazdar AF and Fujisawa T. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 2006; 106: 2200-2207.
79. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T and Date H. Clinicopathologic features of non-small-cell lung cancer with EML4- ALK fusion gene. Ann Surg Oncol 2010; 17: 889-897.
80. Togashi Y, Masago K, Kubo T, Fujimoto D, Sakamori Y, Nagai H, Kim YH, Togashi K and Mishima M. Association between vascularpoor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma. Med Oncol 2012; 29: 3169-3175.
81. Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, Tanaka S, Suga T, Saito R, Ishizuka T, Dobashi K, Minna JD, Nakajima T and Mori M. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 6816-6822.
82. Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, Ichihara S, Suzuki M, Aoe M, Date H, Gazdar AF and Shimizu N. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 2006; 66: 1371-1375.
83. Uhara M, Matsuda K, Taira C, Higuchi Y, Okumura N and Yamauchi K. Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this meth od for the diagnosis of non-small-cell lung cancer. Clin Chim Acta 2009; 401: 68-72.
84. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA Jr and Hirsch FR. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 2009; 4: 318-325.
85. Liam CK, Leow HR, How SH, Pang YK, Chua KT, Lim BK, Lai NL, Kuan YC, Pailoor J and Rajadurai P. Epidermal growth factor receptor mutations in non-small cell lung cancers in a multiethnic malaysian patient population. Asian Pac J Cancer Prev 2014; 15: 321-326.
86. Shi Yeen TN, Pathmanathan R, Shiran MS, Ahmad Zaid FA and Cheah YK. Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients. J Biomed Sci 2013; 20: 22.
87. Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH and Park JY. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007; 173: 107-113.
88. Kang HJ, Lim HJ, Park JS, Cho YJ, Yoon HI, Chung JH, Lee JH and Lee CT. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med 2014; 108: 388-394.
89. Kang SM, Kang HJ, Shin JH, Kim H, Shin DH, Kim SK, Kim JH, Chung KY, Kim SK and Chang J. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 2007; 109: 581-587.
90. Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE and Kim SY. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2012; 75: 321- 325.
91. Kim HR, Lee JC, Kim YC, Kim KS, Oh IJ, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Ryu JS, Jang SH, Son JW, Lee JE, Kim SY, Kim HJ and Lee KY. Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. Lung Cancer 2014; 83: 252-258.
92. Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH and Kim JH. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 2013; 8: 171-178.
93. Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS and Bang YJ. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011; 6: 1474- 1480.
94. Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH and Park JY. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010; 5: 1734-1740.
95. Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, Chung KY, Kim SK, Chang J, Moon JW, Kim H, Choi SH and Kim JH. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol 2009; 135: 1647-1654.
96. Lee YJ, Shim HS, Kang YA, Hong SJ, Kim HK, Kim H, Kim SK, Choi SH, Kim JH and Cho BC. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136: 1937-1944.
97. Na II, Byun BH, Kim KM, Cheon GJ, Choe du H, Koh JS, Lee DY, Ryoo BY, Baek H, Lim SM, Yang SH, Kim CH and Lee JC. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010; 67: 76-80.
98. Na II, Park JH, Choe du H, Lee JK and Koh JS. Association of epidermal growth factor receptor mutations with metastatic presentations in non-small cell lung cancer. ISRN Oncol 2011; 2011: 756265.
99. Oh JE, An CH, Yoo NJ and Lee SH. Detection of low-level EGFR T790M mutation in lung cancer tissues. APMIS 2011; 119: 403-411.
100. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, J�nne PA and Ahn MJ. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009; 4: 809-815.
101. Seo AN, Park TI, Jin Y, Sun PL, Kim H, Chang H and Chung JH. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer 2014; 83: 316-323.
102. Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, Yoo NJ and Lee SH. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005; 446: 483-488.
103. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS and Chung JH. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012; 7: 323- 330.
104. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A and Tan P. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2009; 4: 12-21.
105. Toh CK, Ahmad B, Soong R, Chuah KL, Tan SH, Hee SW, Leong SS, Tan EH and Lim WT. Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. J Thorac Oncol 2010; 5: 17-22.
106. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC and Shih JY. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009; 20: 696-702.
107. Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP, Liu CL, Chen HC, Ku YC, Chen YT, Chang YH, Chen YT, Hsi BL, Tsai SF and Huang SF. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 2006; 53: 311-322.
108. Chang YL, Wu CT, Lin SC, Hsiao CF, Jou YS and Lee YC. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res 2007; 13: 52-58.
109. Chang YL, Wu CT, Shih JY and Lee YC. Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol 2011; 18: 543-550.
110. Lin CC, Hsu HH, Sun CT, Shih JY, Lin ZZ, Yu CJ, Chen GG, Hsin MK, Lam KC, Leung L, Yang CH and Mok T. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. J Thorac Oncol 2010; 5: 1424-1429.
111. Fong Y, Lin YS, Liou CP, Li CF and Tzeng CC. Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. Respirology 2010; 15: 700-705.
112. Wu CC, Hsu HY, Liu HP, Chang JW, Chen YT, Hsieh WY, Hsieh JJ, Hsieh MS, Chen YR and Huang SF. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 2008; 113: 3199-3208.
113. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C and Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15: 4554-4560.
114. Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F and Minarik M. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res 2009; 29: 2767-2773.
115. Maki-Nevala S, Ronty M, Morel M, Gomez M, Dawson Z, Sarhadi VK, Telaranta-Keerie A, Knuuttila A and Knuutila S. Epidermal growth factor receptor mutations in 510 Finnish non-- small-cell lung cancer patients. J Thorac Oncol 2014; 9: 886-891.
116. Pallier K, Houllier AM, Le Corre D, Cazes A, Laurent-Puig P and Blons H. No somatic genetic change in the paxillin gene in nonsmallcell lung cancer. Mol Carcinog 2009; 48: 581- 585.
117. Vallee A, Sagan C, Le Loupp AG, Bach K, Dejoie T and Denis MG. Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples. Int J Oncol 2013; 43: 1045-1051.
118. Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Gruning W, Bauer TT and Mairinger T. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open 2013; 3.
119. Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl WM, Gschwendtner A, Gattenloehner S, Fuchs FS, Schulz C, Rieker RJ, Hartmann A, Ruemmele P and Dietmaier W. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer 2013; 109: 1821-1828.
120. Reinmuth N, Jauch A, Xu EC, Muley T, Granzow M, Hoffmann H, Dienemann H, Herpel E, Schnabel PA, Herth FJ, Gottschling S, Lahm H, Steins M, Thomas M and Meister M. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer 2008; 62: 193-201.
121. Schittenhelm MM, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, St�rkel S, Kanz L, Corless CL, Wong KK, Bokemeyer C and Heinrich MC. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 2009; 8: 481-489.
122. Schmid-Bindert G, Wang Y, Jiang H, Sun H, Henzler T, Wang H, Pilz LR, Ren S and Zhou C. EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients-a comparative study of three different minimal invasive sampling methods. PLoS One 2013; 8: e77948.
123. Wiesweg M, Ting S, Reis H, Worm K, Kasper S, Tewes M, Welt A, Richly H, Meiler J, Bauer S, Hense J, Gauler TC, Kohler J, Eberhardt WE, Darwiche K, Freitag L, Stamatis G, Breitenbucher F, Wohlschlaeger J, Theegarten D, Derks C, Cortes-Incio, Linden G, Skottky S, Lutkes P, Dechene A, Paul A, Markus P, Schmid KW and Schuler M. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. Eur J Cancer 2013; 49: 3076- 3082.
124. Zimmer S, Kahl P, Buhl TM, Steiner S, Wardelmann E, Merkelbach-Bruse S, Buettner R and Heukamp LC. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol 2009; 135: 723-730.
125. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D and Voutsina A. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008; 99: 923-929.
126. Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V and Voutsina A. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010; 69: 110-115.
127. Boldrini L, Ali G, Gisfredi S, Ursino S, Baldini E, Melfi F, Lucchi M, Comin CE, Maddau C, Tibaldi C, Camacci T, Servadio A, Mussi A and Fontanini G. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep 2009; 22: 683-691.
128. Bozzetti C, Negri FV, Azzoni C, Naldi N, Nizzoli R, Bortesi B, Zobbi V, Bottarelli L, Tiseo M, Silini EM and Ardizzoni A. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples. Diagn Cytopathol 2013; 41: 595-598.
129. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A and Varella- Garcia M. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009; 27: 1667-1674.
130. Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A and Crino L. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6: 707-715.
131. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R and Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857-865.
132. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, Viola P, Pullara C, Mucilli F and Buttitta F. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011; 29: 3574-3579.
133. Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crino L and Puma F. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. Am J Clin Oncol 2014; 37: 343-349.
134. Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, Bavieri M, Murer B, Meschiari E, Tamberi S, Cadioli A, Luppi F, Migaldi M and Rossi G. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol 2009; 131: 478-489.
135. Ulivi P, Romagnoli M, Chiadini E, Casoni GL, Capelli L, Gurioli C, Zoli W, Saragoni L, Dubini A, Tesei A, Amadori D and Poletti V. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasoundguided fine needle aspiration in non-small cell lung cancer patients. Int J Oncol 2012; 41: 147-152.
136. Vaguliene N, Zemaitis M, Sarauskas V, Vitkauskiene A and Miliauskas S. The role of mutation status of the epidermal growth factor receptor gene in advanced non-small cell lung cancer. Medicina (Kaunas) 2012; 48: 175- 181.
137. Vincenten J, Smit EF, Vos W, Grunberg K, Postmus PE, Heideman DA, Snijders PJ, Meijer G, Kuik J, Witte BI and Thunnissen E. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1522-1527.
138. Helland A, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jorgensen L, Ariansen S and Brustugun OT. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol 2011; 6: 947-950.
139. Kamila WK, Michal S, Pawel K, Paulina J, Tomasz K, Bozena J, Radoslaw M, Justyna S, Marek S, Trojanowski T, Janusz M and Joanna CW. EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report. Clin Exp Metastasis 2013; 30: 1063-1071.
140. Krawczyk P, Nicos M, Ramlau R, Powrozek T, Wojas-Krawczyk K, Sura S, Jarosz B, Szumilo J, Warda E, Mazurkiewicz T, Sawicki M and Milanowski J. The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma. Pathol Oncol Res 2014; 20: 107- 112.
141. Szumera-Cieckiewicz A, Olszewski WT, Tysarowski A, Kowalski DM, Glogowski M, Krzakowski M, Siedlecki JA, Wagrodzki M and Prochorec- Sobieszek M. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol 2013; 6: 2800- 2812.
142. Castro AS, Parente B, Goncalves I, Antunes A, Barroso A, Conde S, Neves S and Machado JC. Epidermal growth factor receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer. Rev Port Pneumol 2013; 19: 7-12.
143. Moiseyenko VM, Procenko SA, Levchenko EV, Barchuk AS, Moiseyenko FV, Iyevleva AG, Mitiushkina NV, Togo AV, Semionov II, Ivantsov AO, Matsko DE and Imyanitov EN. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma. Onkologie 2010; 33: 231-238.
144. Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E and Hainaut P. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007; 67: 5667-5672.
145. Hlinkova K, Babal P, Berzinec P, Majer I, Mikle- Barathova Z, Piackova B and Ilencikova D. Evaluation of 2-year experience with EGFR mutation analysis of small diagnostic samples. Diagn Mol Pathol 2013; 22: 70-75.
146. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez- Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, S�nchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
147. Isaksson S, Bendahl PO, Salomonsson A, Jonsson M, Haglund M, Gaber A, Jirstrom K, Jonsson P, Borg A, Johansson L, Staaf J and Planck M. Detecting EGFR alterations in clinical specimens-pitfalls and necessities. Virchows Arch 2013; 463: 755-764.
148. Cetin Z, Ozbilim G, Erdogan A, Luleci G and Karauzum SB. Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol 2010; 27: 853- 860.
149. Unal OU, Oztop I, Calibasi G, Baskin Y, Koca D, Demir N, Akman T, Ellidokuz H and Yilmaz AU. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey. Asian Pac J Cancer Prev 2013; 14: 3705-3709.
150. Santis G, Angell R, Nickless G, Quinn A, Herbert A, Cane P, Spicer J, Breen R, McLean E and Tobal K. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS One 2011; 6: e25191.
151. Mariano C, Bosdet I, Karsan A, Ionescu D, Murray N, Laskin JJ, Zhai Y, Melosky B, Sun S and Ho C. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. Lung Cancer 2014; 83: 73-77.
152. Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Ma�tre A, Gandara D, Johnson DH, Rigas JR, Seymour L and Shepherd FA. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in nonsmall cell lung cancer. J Thorac Oncol 2011; 6: 139-147.
153. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I and Johnson FM. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009; 15: 4423-4430.
154. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W and Ladanyi M. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009; 28: 2773-2783.
155. D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V and Azzoli CG. Distinct clinical course of EGFRmutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012; 7: 1815-1822.
156. Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV and Danenberg KD. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 2010; 5: 1933-1938.
157. Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G and Pao W. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 2012; 39: 366-372.
158. Hoque MO, Brait M, Rosenbaum E, Poeta ML, Pal P, Begum S, Dasgupta S, Carvalho AL, Ahrendt SA, Westra WH and Sidransky D. Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer. J Thorac Oncol 2010; 5: 1887-1893.
159. Munfus-McCray D, Harada S, Adams C, Askin F, Clark D, Gabrielson E and Li QK. EGFR and KRAS mutations in metastatic lung adenocarcinomas. Hum Pathol 2011; 42: 1447-1453.
160. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M and Riely GJ. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29: 2046-2051.
161. Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG and Riely GJ. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer 2012; 118: 5840-5847.
162. Sequist LV, Joshi VA, J�nne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE and Lynch TJ. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007; 12: 90-98.
163. Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, Sakamoto M and Hirohashi S. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci 2007; 98: 985-991.
164. Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD and Wistuba II. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009; 15: 4829-4837.
165. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A and Wistuba I. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006; 1: 231-239.
166. Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M and Kris MG. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 2011; 6: 28-31.
167. Rahman S, Kondo N, Yoneda K, Takuwa T, Hashimoto M, Orui H, Okumura Y, Tanaka F, Kumamoto K, Mostafa MG, Chowdhury GM, Haque A and Hasegawa S. Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung. Int J Clin Oncol 2014; 19: 45-49.
168. Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar N and Dutt A. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One 2013; 8: e76164.
169. Doval DC, Azam S, Batra U, Choudhury KD, Talwar V, Gupta SK and Mehta A. Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study. J Carcinog 2013; 12: 12.
170. Mehmood T, Rashid A, Usman S, Irfan M, Haider I and Rehman K. 5P EGFR Gene mutation in advanced non-small cell lung cancer. Lung Cancer 2013; 80: S2.
171. Bacchi CE, Ciol H, Queiroga EM, Benine LC, Silva LH and Ojopi EB. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics (Sao Paulo) 2012; 67: 419-424.
172. Carneiro JG, Couto PG, Bastos-Rodrigues L, Bicalho MA, Vidigal PV, Vilhena A, Amaral NF, Bale AE, Friedman E and De Marco L. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. Genet Res (Camb) 2014; 96: e002.
173. Honma HN, Perroud MW Jr, Leme MS, Barbeiro AS, Saad BA, Morcillo AM, Vassallo J, Costa DB and Zambon L. EGFR activating mutations and their association with response to platinumdoublet chemotherapy in Brazilian non-small cell lung cancer patients. Target Oncol 2014; 9: 389-94.
174. Cooper WA, Yu B, Yip PY, Ng CC, Lum T, Farzin M, Trent RJ, Mercorella B, Clarkson A, Kohonen- Corish MR, Horvath LG, Kench JG, McCaughan B, Gill AJ and O'Toole SA. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. J Clin Pathol 2013; 66: 744-748.
175. Sriram KB, Tan ME, Savarimuthu SM, Wright CM, Relan V, Stockwell RE, Clarke BE, Duhig EE, Yang IA, Bowman RV and Fong KM. Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. Eur Respir J 2011; 38: 903-910.
176. Webb S, Thomas M, Metcalf C, Segal A, Nowak AK, Bentel J and Millward M. EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia. Asia Pac J Clin Oncol 2009; 5: 66-71.
177. Errihani H, Inrhaoun H, Boukir A, Kettani F, Gamra L, Mestari A, Jabri L, Bensouda Y, Mrabti H and Elghissassi I. Frequency and type of epidermal growth factor receptor mutations in moroccan patients with lung adenocarcinoma. J Thorac Oncol 2013; 8: 1212-1214.
178. Gaughan EM, Cryer SK, Yeap BY, Jackman DM and Costa DB. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer 2013; 79: 193- 197.
179. Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, Shimizu T, Takeuchi H, Yano M, Fukai I and Fujii Y. EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 2005; 11: 2924-2929.
180. Sequist LV, Joshi VA, J�nne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE and Lynch TJ. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007; 12: 90-98.
181. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H and Ji H. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010; 28: 4616-4620.